R&D optics
The same AI spend can appear as a capitalised intangible or as an R&D expense line, and the two read very differently to investors. Capitalising signals a durable asset and lifts current earnings; expensing signals ongoing investment and depresses them. Which reads as higher quality is a genuine debate, not a settled answer.
Two presentations of the same cash
IAS 38's restriction means much AI spend is expensed as research, so it appears as period cost rather than an asset IAS 38§54. Where a build qualifies, capitalising presents the same cash as an asset. Investors comparing peers must therefore look through the accounting to the underlying spend.
The signalling debate
One view treats capitalising as prudent matching of cost to the periods the asset benefits. Another treats heavy capitalisation of uncertain internal software as an aggressive lever that flatters current earnings and defers the reckoning. There is no consensus position, and analysts frequently adjust reported figures to a consistent basis before comparing companies.
What this means for the policy choice
Because the optics cut both ways, the defensible course is to apply the recognition tests faithfully and disclose the policy clearly, rather than to select the treatment for its earnings effect. The accounting should follow the facts, and the disclosure should let a reader reconstruct the underlying spend.
- S1IAS 38 Intangible Assets, IFRS Foundation (IFRS). https://www.ifrs.org/issued-standards/list-of-standards/ias-38-intangible-assets/
- S2Handbook: Software and website costs (ASC 350-40 internal-use software), KPMG (US GAAP). https://kpmg.com/us/en/frv/reference-library/2026/handbook-software-website-costs.html